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Background
Drug desensitization is the induction of temporary clinical
unresponsiveness to drug antigens to which patients have
presented severe hypersensitivity reactions (HSR). Rapid
desensitization in patients suffering immediate hypersensi-
tivity reactions with chemotherapeutic agents and mono-
clonal antibodies have been widely described and have
shown to be successful. Non-immediate hypersensitivity
reactions with other drugs have usually required desensiti-
zation with several days’ protocols to achieve total doses.
Method
Forty three desensitization procedures were performed
in 6 patients with a 12-13 step, 6-hour protocol. All
patients had developed a delayed maculopapular rash
with the use of chemotherapeutic and/or biological
agents. Four patients were pretreated with corticoster-
oids, paracetamol and antihistamines before each desen-
sitization procedure.
Results
All the 43 desensitizations undertaken were successfully
completed (Temozolamide 25, Bendamustine 4, Rituxi-
mab 4, Infliximab 5 and Gemcitabina 5). We observed
HSR during 11 (25%) of desensitizations, including 5
inmediate exantema, 3 delayed local macular exantema
and 3 delayed maculopapular lesions. Four patients were
treated with corticosteroids and anti-histamines after
the desensitization protocol to avoid more delayed HSR.
Conclusions
Rapid desensitization protocols are safe and effective in
getting over delayed HSR to chemotherapeutic and
monoclonal antibodies and allow patients with severe
diseases to continue their treatment.
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